May 25, 2020
OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)(1)
Mar 09, 2020
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
Jan 09, 2020
Visiongain Report Claims There is Huge Potential Within the $5.9bn Anti-Idiopathic Pulmonary Fibrosis Drugs Market
Nov 07, 2019
New analysis of patients with autoimmune-related ILDs in the INBUILD study shown as poster presentation at the 2019 ACR/ARP Annual Meeting
Oct 10, 2019
FDA Grants Ofev® Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
Oct 09, 2019
New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype(1)
Jul 25, 2019
FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD
May 20, 2019
Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD
May 20, 2019
Promedior Announces Positive Long-term Safety and Efficacy Data from Open Label Extension Study of PRM-151 in Idiopathic Pulmonary Fibrosis
May 19, 2019
Bridge Biotherapeutics Announces Data Presentation from First-in-Human Study of BBT-877 for Idiopathic Pulmonary Fibrosis
Mar 18, 2019
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
Dec 16, 2018
Bridge Biotherapeutics Announces FDA Clearance of IND for its BBT-877, an Autotaxin Inhibitor for IPF
Nov 18, 2018
Bridge Biotherapeutics Files Investigational New Drug Application for BBT-877, an Autotaxin Inhibitor for Idiopathic Pulmonary Fibrosis
Aug 22, 2018
Bridge Biotherapeutics Presented Preclinical Study Results on BBT-877, an Autotaxin inhibitor at the IPF Summit 2018
May 22, 2018
Prometic presents new clinical data on PBI-4050 for the treatment of idiopathic pulmonary fibrosis
Mar 19, 2018
FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
Feb 20, 2018
Prometic Announces Realignment of its Clinical Program Priorities for 2018
Jan 29, 2018
Prometic's PBI-4050: Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis (IPF) Finalized
Dec 15, 2017
Global Anti-idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2027
Dec 11, 2017
Prometic's PBI-4050 Receives Promising Innovative Medicine (PIM) Designation From The UK MHRA In The Treatment Of Idiopathic Pulmonary Fibrosis